Claims for Patent: 9,211,304

Summary for Patent: 9,211,304

Title:	Therapy-enhancing glucan
Abstract:	This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.
Inventor(s):	Cheung; Nai-Kong V. (New York, NY), Engstad; Rolf Einar (Tromoso, NO)
Assignee:	Sloan-Kettering Institute for Cancer Research (New York, NY) BIOTEC PHARMACON ASA (Oslo, NO)
Application Number:	13/760,307
Patent Claims:	1. A method of treating cancer in a subject, comprising administering to said subject a soluble .beta.-glucan in an amount effective to treat said cancer, wherein said glucan is derived from yeast and comprises a .beta.-1,3 backbone with branches attached to the backbone via .beta.-1,6 linkages, wherein the glucose units in said branches are .beta.-1,3 linked, and said cancer is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, non-small cell lung cancer, colorectal cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma, and epidermoid carcinoma. 2. The method of claim 1, wherein said glucan has a molecular weight of 10-350 kDa. 3. The method of claim 1, wherein said glucan is administered orally or intravenously. 4. The method of claim 1, wherein said glucan is administered at about 25 mg/kg/day. 5. The method of claim 1, further comprising administering a complement-activating antibody. 6. The method of claim 5, wherein said antibody is a monoclonal antibody. 7. The method of claim 5, wherein said antibody is administered simultaneously or sequentially with said glucan. 8. The method of claim 5, wherein said antibody is selected from the group consisting of cetuximab, M195, Dacluzimab, R24, Herceptin, Rituximab, 528, IgG, IgM, IgA, C225, Epratuzumab and 3F8. 9. The method of claim 5, wherein said antibody is cetuximab for treating non-small cell lung cancer. 10. The method of claim 5, wherein said antibody is cetuximab for treating colorectal cancer. 11. The method of claim 5, wherein said antibody is rituximab for treating non-Hodgkin's lymphoma. 12. The method of claim 1, further comprising administering a chemotherapeutic agent. 13. The method of claim 12, wherein said chemotherapeutic agent is carboplatin. 14. The method of claim 12, wherein said chemotherapeutic agent is irinotecan. 15. The method of claim 12, wherein said chemotherapeutic agent is paclitaxel. 16. The method of claim 12, wherein said glucan has a molecular weight of 10-350 kDa. 17. The method of claim 12, wherein said glucan is administered orally or intravenously. 18. The method of claim 12, wherein said glucan is administered at about 25 mg/kg/day. 19. The method of claim 12, wherein said chemotherapeutic agent is administered simultaneously or sequentially with said glucan. 20. The method of claim 12, wherein the cancer is non-small cell lung cancer.

Details for Patent 9,211,304

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2023-07-16
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2023-07-16
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2023-07-16